ZME Science
No Result
View All Result
ZME Science
No Result
View All Result
ZME Science

Home → Health

Better than expected: Pfizer’s coronavirus vaccine prevents 90% of infections

It's still just interim data, but it looks good.

Mihai AndreibyMihai Andrei
November 9, 2020
in Health, News
A A
Share on FacebookShare on TwitterSubmit to Reddit

The coronavirus vaccine from Pfizer and BioNTech seems to be more effective than thought, without producing any serious safety concerns. However, the interim analysis comes from just 94 out of over 43,000 enrolled participants.

Record-breaking speed

An announcement by the two companies notes that the mRNA vaccine candidate seems to prevent 90% of COVID-19 cases after the second dose of vaccine. Officials were thrilled.

“The first interim analysis of our global Phase 3 study provides evidence that a vaccine may effectively prevent COVID-19. This is a victory for innovation, science and a global collaborative effort,” said Prof. Ugur Sahin, BioNTech co-founder and CEO. “When we embarked on this journey 10 months ago this is what we aspired to achieve.”

This is the first vaccine to be tested in the United States to generate late-stage data (although it is also being tested outside the US). Currently, 43,538 volunteers are enrolled in the study, with 38,955 of them having already received their second dose. Globally, 42% of study participants have racially and ethnically diverse backgrounds.

For months, researchers have warned that a Pfizer vaccine may only be effective in 60-70% of the cases. But if the interim data stands up, the results are much better.

“Today is a great day for science and humanity. The first set of results from our Phase 3 COVID-19 vaccine trial provides the initial evidence of our vaccine’s ability to prevent COVID-19,” said Dr. Albert Bourla, Pfizer Chairman and CEO.

The two companies will wait until they gather 2 months of safety data, as per FDA recommendations, and only then will ask for emergency regulation. No major side effects were observed so far although aches and fevers have been reported in some cases.

“We look forward to sharing additional efficacy and safety data generated from thousands of participants in the coming weeks,” Bourla added.

But while this is important news and could mark a turning point in our fight against the pandemic, it’s important to also note some caveats.

Sparse details

For starters, this is just interim data: out of over 43,000 participants, this data only covers 94 — it’s not uncommon for interim data to be confirmed by the whole group, but it’s also not uncommon for results to change. Furthermore, the data have not been released for analysis and have not been peer-reviewed by external experts, only by company scientists. So overall, we don’t have that many details about the vaccine candidate.

RelatedPosts

Vaccine manufacturers tell Congress they’re ready to double, maybe triple production
A thorough comparison of the Pfizer and Moderna COVID-19 vaccines
Measles Doesn’t Just Make You Sick. It Resets Your Immune System
What’s the cheapest COVID-19 vaccine ?

Even if results are confirmed, which would be what officials are hoping for, there will be major distribution problems. The vaccine needs to be stored at ultra-cold temperatures, which makes delivery and storage very difficult. Pfizer is confident that the challenges can be overcome and expects 50 million doses to be delivered by the end of 2020, with another 1.3 billion by the end of 2021.

There’s also no way to tell for sure how long the vaccine will protect against infection since the study itself has only been running for a few months. Previous studies, however, suggest that it could last for months before waning, although revaccination will probably be needed in time.

We will need to see the full data and evaluate it independently, yet overall, the results seem to bode well — not just for Pfizer, but for other companies working on late-stage vaccines.

This announcement comes right on the back of another one by British-Swedish company AstraZeneca, which said they can have a working vaccine by the end of the year, if regulatory bodies move fast. Moderna, another company working on an mRNA vaccine should also be pretty happy to hear the news.

Having a working vaccine developed in less than a year is even better than the optimistic prognoses laid down when the pandemic started. The stakes have never been higher, and research companies seem to be delivering on their promise.

“There’s a lot at stake for humanity,” Dr. Bourla said. “If we get it right, the world can be saved.”

Tags: Biontechcoronaviruspfizervaccine

ShareTweetShare
Mihai Andrei

Mihai Andrei

Dr. Andrei Mihai is a geophysicist and founder of ZME Science. He has a Ph.D. in geophysics and archaeology and has completed courses from prestigious universities (with programs ranging from climate and astronomy to chemistry and geology). He is passionate about making research more accessible to everyone and communicating news and features to a broad audience.

Related Posts

Health

RFK Jr, Nation’s Top Health Official, Refuses to Recommend the Measles Vaccine, Says ‘I Don’t Think People Should Be Taking Medical Advice from Me’

byTudor Tarita
2 days ago
Health

Jay Bhattacharya has a history of misinformation. He’s about to head the NIH

byMihai Andrei
2 months ago
Diseases

Measles Doesn’t Just Make You Sick. It Resets Your Immune System

byMihai Andrei
3 months ago
Diseases

Roald Dahl Lost His Daughter to Measles. His Heartbreaking Letter on Vaccination Is Very Relevant Today

byMihai Andrei
3 months ago

Recent news

This Startup Is Using Ancient DNA to Recreate Perfumes from Extinct Flowers

May 21, 2025

Jupiter Was Twice Its Size and Had a Magnetic Field 50 Times Stronger After the Solar System Formed

May 21, 2025

How One Man and a Legendary Canoe Rescued the Dying Art of Polynesian Navigation

May 21, 2025 - Updated on May 22, 2025
  • About
  • Advertise
  • Editorial Policy
  • Privacy Policy and Terms of Use
  • How we review products
  • Contact

© 2007-2025 ZME Science - Not exactly rocket science. All Rights Reserved.

No Result
View All Result
  • Science News
  • Environment
  • Health
  • Space
  • Future
  • Features
    • Natural Sciences
    • Physics
      • Matter and Energy
      • Quantum Mechanics
      • Thermodynamics
    • Chemistry
      • Periodic Table
      • Applied Chemistry
      • Materials
      • Physical Chemistry
    • Biology
      • Anatomy
      • Biochemistry
      • Ecology
      • Genetics
      • Microbiology
      • Plants and Fungi
    • Geology and Paleontology
      • Planet Earth
      • Earth Dynamics
      • Rocks and Minerals
      • Volcanoes
      • Dinosaurs
      • Fossils
    • Animals
      • Mammals
      • Birds
      • Fish
      • Amphibians
      • Reptiles
      • Invertebrates
      • Pets
      • Conservation
      • Animal facts
    • Climate and Weather
      • Climate change
      • Weather and atmosphere
    • Health
      • Drugs
      • Diseases and Conditions
      • Human Body
      • Mind and Brain
      • Food and Nutrition
      • Wellness
    • History and Humanities
      • Anthropology
      • Archaeology
      • History
      • Economics
      • People
      • Sociology
    • Space & Astronomy
      • The Solar System
      • Sun
      • The Moon
      • Planets
      • Asteroids, meteors & comets
      • Astronomy
      • Astrophysics
      • Cosmology
      • Exoplanets & Alien Life
      • Spaceflight and Exploration
    • Technology
      • Computer Science & IT
      • Engineering
      • Inventions
      • Sustainability
      • Renewable Energy
      • Green Living
    • Culture
    • Resources
  • Videos
  • Reviews
  • About Us
    • About
    • The Team
    • Advertise
    • Contribute
    • Editorial policy
    • Privacy Policy
    • Contact

© 2007-2025 ZME Science - Not exactly rocket science. All Rights Reserved.